Most recently dba Vaxin Inc., the firm now renamed Altimmune Inc. (NASDAQ:ALT) - is organized around infectious diseae therapies. Anchored originally in IP licensed from the University of Alabama Birmingham, the firm went through a reverse merger with PharmAthene Inc January 2017 and since then has raised significant additional funding. Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates.
